{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:25:25Z","timestamp":1774682725919,"version":"3.50.1"},"reference-count":12,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1507\/endocrj.ej12-0166","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T05:33:52Z","timestamp":1342244032000},"page":"1051-1056","source":"Crossref","is-referenced-by-count":18,"title":["A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome"],"prefix":"10.1507","volume":"59","author":[{"given":"Keiichi","family":"Torimoto","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Arao","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Mori","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. <i>Cochrane Database Syst Rev<\/i> Jul 20;(3): CD003474","DOI":"10.1002\/14651858.CD003474.pub2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cheuk Chun Szeto, Kai Ming Chow (2005) Nephrotoxicity Related to New Therapeutic Compounds. <i>Ren Fail<\/i> 27: 329-333.","DOI":"10.1081\/JDI-56595"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Janssen Van Doorn K, Neyns B, Van der Niepen P, Verbeelen D (2001) Pamidronate &ndash;related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. <i>Nephron<\/i> 89: 467-468.","DOI":"10.1159\/000046123"},{"key":"4","unstructured":"4. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, <i>et al.<\/i> (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. <i>Cancer J<\/i> 7: 377-387."},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00071.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7. Bodmer M, Amico P, Mihatsch MJ, Haschke M, Kummer O, <i>et al.<\/i> (2007) Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. <i>Nephrol Dial Transplant<\/i> 22: 2366-2370.","DOI":"10.1093\/ndt\/gfm209"},{"key":"7","unstructured":"8. Koike K, Fukami K, Morishige S, Hazama T, Taguchi K, <i>et al.<\/i> (2009) Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma. <i>Jpn J Nehorol<\/i> 51: 557-562 (In Japanese)."},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.356"},{"key":"9","doi-asserted-by":"crossref","unstructured":"11. Guarneri V, Donati S, Nicolini M, Giovannelli S, D &rsquo;Amico R, <i>et al.<\/i> (2005) Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. <i>Oncologist<\/i> 10: 842-848.","DOI":"10.1634\/theoncologist.10-10-842"},{"key":"10","doi-asserted-by":"crossref","unstructured":"12. Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. <i>Osteoporos Int <\/i>9Suppl 2: S66-80.","DOI":"10.1007\/PL00004164"},{"key":"11","doi-asserted-by":"crossref","unstructured":"14. Coxon FP, Thompson K, Rogers MJ (2006) Recent advances in understanding the mechanism of action of bisphosphonates. <i>Curr Opin Pharmacol<\/i> 6: 307-312.","DOI":"10.1016\/j.coph.2006.03.005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"15. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, <i>et al.<\/i> (2008) V&gamma;9V&delta;2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab. <i>Int J Cancer<\/i> 122: 2526-2534.","DOI":"10.1002\/ijc.23365"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/59\/12\/59_EJ12-0166\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:32:12Z","timestamp":1618295532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/59\/12\/59_EJ12-0166\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej12-0166","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}